MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER

Clinical trials for MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER explained in plain language.

Never miss a new study

Get alerted when new MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER trials appear

Sign up with your email to follow new studies for MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 1

New cancer drug enters human testing for Tough-to-Treat tumors

Disease control Recruiting now

This early-stage study aims to find a safe and effective dose of a new drug called EIK1005 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will test EIK1005 by itself and combined with an existing immunotherapy drug (pembrolizum…

Matched conditions: MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER

Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER

Get alerted when new MSI-H/DMMR GASTROESOPHAGEAL-JUNCTION CANCER trials appear

New cancer drug enters human testing for Tough-to-Treat tumors